<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03757130</url>
  </required_header>
  <id_info>
    <org_study_id>20170139</org_study_id>
    <nct_id>NCT03757130</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study of AMG 598 in Subjects With Obesity</brief_title>
  <official_title>A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 598 in Subjects With Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multiple ascending dose study in
      subjects with obesity. AMG 598 will be evaluated in approximately 108 subjects to assess
      safety, tolerability, pharmacokinetics and pharmacodynamic effects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 26, 2018</start_date>
  <completion_date type="Actual">December 16, 2019</completion_date>
  <primary_completion_date type="Actual">December 16, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Subject incidence of treatment-emergent adverse events</measure>
    <time_frame>up to 263 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter of maximum observed concentration (Cmax)</measure>
    <time_frame>up to 263 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter of time of maximum observed concentration (tmax)</measure>
    <time_frame>up to 263 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter of area under the concentration time curve (AUC)</measure>
    <time_frame>up to 263 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>AMG 598</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending dose cohorts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-controlled</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple ascending dose cohorts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 598, liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending dose cohorts
Additionally liraglutide is escalated to a dose of 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo controlled, liraglutide</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple ascending dose cohorts
Additionally liraglutide is escalated to a dose of 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 598, stable liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 598 at a to be determined (TBD) dose in addition to liraglutide 3.0 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo controlled, stable liraglutide</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo at a to be determined (TBD) volume in addition to liraglutide 3.0 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 598</intervention_name>
    <description>AMG 598 dose</description>
    <arm_group_label>AMG 598</arm_group_label>
    <arm_group_label>AMG 598, liraglutide</arm_group_label>
    <arm_group_label>AMG 598, stable liraglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Calculated volume to match experimental drug.</description>
    <arm_group_label>Placebo controlled, liraglutide</arm_group_label>
    <arm_group_label>Placebo controlled, stable liraglutide</arm_group_label>
    <arm_group_label>Placebo-controlled</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Daily SC injection of liraglutide</description>
    <arm_group_label>AMG 598, liraglutide</arm_group_label>
    <arm_group_label>AMG 598, stable liraglutide</arm_group_label>
    <arm_group_label>Placebo controlled, liraglutide</arm_group_label>
    <arm_group_label>Placebo controlled, stable liraglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women with ages between 18 and 65 years old, inclusive, at time of signing
             consent

          -  Body mass index (BMI) between greater than or equal to 30.0 kg/m2 and less than or
             equal to 40.0 kg/m2 at screening

          -  Except for obesity, otherwise healthy or medically stable per protocol

          -  Have a stable body weight defined as less than 5 kg self-reported change during the
             previous 8 weeks prior to screening

          -  Other Inclusion criteria may apply

          -  Stable on liraglutide, depending on cohort

        Exclusion Criteria:

          -  History or clinical evidence of diabetes

          -  Inadequate organ function at screening

          -  Currently receiving treatment in another investigational device or drug study

          -  Women who are pregnant/lactating/breastfeeding or who plan to become
             pregnant/breastfeed while on study through 5 months after receiving the last dose of
             investigational product

          -  History or evidence of a clinically significant disorder, condition or disease that
             would pose a risk to subject safety or interfere with the study evaluation, procedures
             or completion

          -  A family or personal history of medullary thyroid carcinoma or multiple endocrine
             neoplasia type 2; a personal history of non-familial medullary thyroid carcinoma;
             confirmed chronic pancreatitis or idiopathic acute pancreatitis, or gallbladder
             disease (ie, cholelithiasis or cholecystitis) not treated with cholecystectomy, for
             cohorts receiving liraglutide

          -  History of major depressive disorder

          -  Other Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 27, 2018</study_first_submitted>
  <study_first_submitted_qc>November 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2018</study_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.</ipd_access_criteria>
    <ipd_url>http://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

